Related Experiment Video
Updated: Jul 15, 2026
08:59
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis?
Elijah W Stommel1, David Graber, Justin Montanye
1Department of Medicine, Section of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. elijah.w.stommel@hitchcock.org
Medical Hypotheses
|May 4, 2007
Summary
Amyotrophic lateral sclerosis (ALS) rarely occurs in schizophrenia patients. Chronic use of neuroprotective psychiatric medications like neuroleptics and antidepressants may protect against ALS, offering new therapeutic insights.
Area of Science:
- Neuroscience
- Neurology
- Psychiatry
Background:
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease.
- Schizophrenia is a common psychiatric disorder.
- The co-occurrence of ALS and schizophrenia is notably rare.
Purpose of the Study:
- To investigate the potential protective effect of psychiatric medications on ALS development.
- To explore the neuroprotective and neurogenesis-promoting properties of neuroleptics and antidepressants.
Main Methods:
- Observational analysis by neuromuscular specialists at major ALS centers.
- Review of existing literature on schizophrenia, ALS, and psychotropic drug effects.
Main Results:
- A rare incidence of ALS observed in schizophrenia patients.
- Hypothesized protective role of chronic neuroleptic and antidepressant use.
Conclusions:
- Neuroleptics and antidepressants may offer neuroprotection against ALS.
- These findings suggest novel therapeutic strategies for ALS and insights into its pathophysiology.
Related Concept Videos
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
01:29Psychological and Sociocultural Causes of Schizophrenia
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...